Bristol-Myers Squibb

In December 2016, Bristol-Myers Squibb was granted exclusive worldwide rights to NG-348. PsiOxus will lead pre-IND activities and Bristol-Myers Squibb is responsible for all clinical development and commercialization. View the partnership announcement.


Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu